



CODEN [USA]: IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<https://doi.org/10.5281/zenodo.7561933>Available online at: <http://www.iajps.com>

Review Article

**METHOTREXATE INDUCED FOLATE DEFICIENCY IN
PATIENTS WITH RHEUMATOID ARTHRITIS: A REVIEW****Dr Santhosh Uttangi¹, J.S Venkatesh², Rajasree Reghunath³,
Reshma Roy⁴, Ranjini T P⁵, Pooja S Raj⁶**¹Assistant Professor, Department of Pharmacy Practice, SCS College Of Pharmacy,
Harapanahalli²Head of the Department, Department of Pharmacy Practice, SCS College Of Pharmacy,
Harapanahalli³⁻⁶Pharm D Interns, SCS College Of Pharmacy, Harapanahalli**Article Received:** November 2022 **Accepted:** December 2022 **Published:** January 2023**Abstract:**

Objectives: The folate antagonist methotrexate (MTX) has become established as the most commonly used disease-modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA), but it is frequently discontinued due to adverse effects. The negative effects are thought to be mediated by folate antagonism. In this paper, we summarise the current data on the use of folates as a supplement to MTX in RA for the prevention of adverse effects and as a potential modulator of cardiovascular risk, and we propose guidelines for standard practise. Methods: A Medline search was conducted using the terms 'methotrexate,' 'folic acid,' 'folinic acid,' 'folate,' and 'homocysteine'. The literature on the use of folates as a supplement to MTX in the treatment of RA was reviewed, and other papers referred to as references were investigated. Results: Supplemental folates, such as folic and folinic acid, have been shown to improve MTX adherence by lowering the incidence of liver function test abnormalities and gastrointestinal intolerance. Folate supplements do not appear to reduce the effectiveness of MTX in the treatment of RA. Furthermore, supplemental folic acid reduces the increase in plasma homocysteine caused by MTX use. This may reduce the risk of cardiovascular disease, which is over-represented in RA patients and for which hyperhomocysteinaemia is now recognised as an independent risk factor. Conclusions: We propose that all patients receiving MTX for the treatment of RA be given folic acid supplements on a regular basis. We recommend a practical dosing schedule of 5 mg of oral folic acid given the morning after MTX administration.

Key words: Methotrexate, Folic acid, Folinic acid, Homocysteine.

Corresponding author:**Dr.Santhosh Uttangi,**

Assistant Professor,

Department of Pharmacy practice, S.C.S. College of Pharmacy,

Harapanahalli, Karnataka, India

QR code



Please cite this article in press **Santhosh Uttangi et al, Methotrexate Induced Folate Deficiency In Patients With Rheumatoid Arthritis: A Review., Indo Am. J. P. Sci, 2023; 10 (01).**

INTRODUCTION:

Methotrexate (MTX) has become the most widely used disease-modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA), and it is also widely used in other inflammatory conditions.¹ There has been a trend in recent years toward more aggressive use of MTX in the treatment of inflammatory arthropathies, in terms of both dose and early intervention. MTX is also involved in the use of some tumour necrosis factor-blocking monoclonal antibodies. The current data on the use of folic acid as a supplement to MTX use in RA for the prevention of adverse effects and as a potential modulator of cardiovascular risk are summarized in this review. Aminopterin, a folic acid analogue, was first used to treat RA in 1951.^(1,3) By 1972, it had been demonstrated that the related compound MTX (N-10-methylaminopterin) reduced disease activity⁴, and it has since become the first-line DMARD in the treatment of RA due to its superior efficacy:toxicity profile.⁵

MECHANISM OF ACTION

Despite being in use for more than 30 years, the precise mechanism of action of MTX in the treatment of RA is unknown. MTX inhibits the enzyme dihydrofolate reductase, depleting the pool of reduced folates, which act as donors of 1-carbon moieties in the formation of metabolic intermediates such as purines, deoxythymidylate monophosphate, and methionine, and causing a state of effective folate deficiency.¹ In high doses, such as those used in cancer chemotherapy, MTX acts as a cytotoxic drug by interfering with purine and pyrimidine synthesis in tissues with a high rate of cellular turnover. However, there is no evidence that the beneficial effect of MTX in a low, once-weekly dose is mediated by inhibition of immune or inflammatory cell replication.¹ At the doses used to treat RA, MTX is likely to act through a variety of intracellular pathways. MTX is converted to polyglutamated forms in cells, which promote intracellular retention. These intracellular polyglutamates are strong inhibitors of dihydrofolate reductase as well as a number of folate-dependent enzymes, including 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase.^(1,6) AICAR accumulation increases adenosine release into the extracellular space. Adenosine exerts an anti-inflammatory effect by interacting with neutrophil and mononuclear cell receptors.^(1,7) MTX also influences cytokine responses at multiple levels and may promote apoptosis in activated lymphocytes.⁶ These and other mechanisms could all play a role in MTX's clinical effects. Current evidence suggests that adenosine

plays a critical role in a pathway that is not dependent on dihydrofolate reductase.¹

ADVERSE EFFECTS AND FOLATE SUPPLEMENTATION:

Despite its efficacy as a disease-modifying agent in RA, the likelihood of discontinuing MTX one year after starting therapy is 30%.⁸ The occurrence of adverse effects is the most important factor influencing the decision to discontinue the drug.⁸ These are classified as minor side effects, such as mouth ulcers and gastrointestinal intolerance, and major side effects, which include bone marrow toxicity and abnormal liver function tests. Some of these side effects are likely due to folate antagonism, and several, such as gastrointestinal intolerance, cytopenias, and alopecia, are similar to those seen in folate deficiency states. Furthermore, MTX toxicity is associated with folate deficiency.^(3,9) Cellular folate stores are reduced in RA patients taking MTX.^(9,10) Elevated erythrocyte mean corpuscular volume (MCV) has been linked to MTX toxicity and has been proposed as a predictor of early toxicity.^(10,11) However, this relationship has not been replicated in all studies, which may reflect MCV's insensitivity as a measure of intracellular folate stores.^(10,12,13)

While there is a theoretical basis for using folate supplements to reduce adverse effects, there is currently no agreement on the use of folate supplements in patients taking low-dose MTX. Regional and national differences in practice persist. Since the early 1990s, folate supplementation has become standard practice in the United States, but practice in the United Kingdom and Europe has varied. According to the British Society of Rheumatology guidelines for second-line drug monitoring, regular folic acid (FA) supplements are thought to reduce toxicity¹⁴, whereas guidelines in the United States recommend that folate supplementation be considered in all patients taking MTX.¹⁵ There is no clear explanation for this difference in practice, but it has most likely caused some confusion and identified a need for evidence base clarification.

In the early 1990s, the first randomised controlled trials of folic acid supplementation in MTX-treated RA patients were conducted.^(3,10) MTX toxicity was significantly reduced at 6 and 12 months in patients receiving supplemental folic acid at 1 mg per day in the first trial and either 5 or 27.5 mg per week in the second; there was no difference in benefit between the two folic acid doses. Only these two trials were included in a meta-analysis of trials assessing the benefits of either folic acid or folinic acid

supplementation.⁹ This study found that folic acid supplementation significantly reduced the risk of mucosal and gastrointestinal (GI) side effects (odds ratio 0.21, 95% confidence interval 0.10-0.44). There was insufficient evidence to show an effect on cytopenias or liver enzyme abnormalities. Similarly, a meta-analysis of five trials evaluating the use of folic acid supplementation revealed a decrease in GI and mucosal side effects. When folic acid doses greater than 5 mg per week were used, this benefit was lost.⁹ Folic and folinic acid were recently directly compared in a large randomised trial of 434 MTX-treated patients conducted in the Netherlands over 48 weeks.¹⁶ Folic acid, at 1 mg daily, and folinic acid, at 2.5 mg per week, both reduced the rate of MTX discontinuation in RA patients who started the drug. The two folate supplements provided the same benefit. In this trial, the difference in MTX continuation rates between the folate and placebo groups was almost entirely explained by increases in hepatic transaminases; however, unlike the meta-analysis of folate supplementation, treatment did not appear to reduce GI symptoms such as nausea, abdominal pain, and stomatitis. A randomised, double-blind study of 75 patients on MTX and folic acid for an average of 30 months found that substituting placebo for folic acid 5 mg daily was associated with a significantly increased risk of discontinuing MTX therapy due to adverse effects, as well as a significantly increased incidence of nausea.¹² A small study of 14 patients

with a sustained elevation of serum ALT (alanine transaminase) while taking MTX found that folic acid administration caused ALT to decrease in all patients within 3 months.¹⁷ A recent study of 236 patients taking MTX found an increased risk of discontinuing MTX treatment in patients with the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene.¹⁸ This supports the theory that the hepatic toxicity associated with MTX may be mediated by impaired homocysteine metabolism. The mutated gene causes decreased conversion of 5,10-methyleneTHF to methylTHF, preventing homocysteine remethylation to methionine and resulting in homocysteine accumulation.

Because rapidly dividing cells in the bone marrow are vulnerable to folate deficiency, folate supplementation may reduce the risk of MTX-induced cytopenias. Only nine of 434 patients taking MTX for RA at doses ranging from 7.5 to 25 mg per week developed leucopenia. Two were given a placebo, four were given folic acid, and three were given folinic acid. In three patients (two placebo, one folic acid), adverse haematological effects necessitated MTX withdrawal.¹⁶ A retrospective study linked MTX-related haematological toxicity to a lack of folate.¹¹ However, insufficient patient numbers have been included in prospective studies to detect a protective effect of folic acid supplementation

Table 1: Folate use suggested in RA patients taking MTX

	Indication	Benefit
Folic acid	All patients taking MTX	5-10mg once weekly by month given morning after MTX dose
		Dose Reduction of side effects (LFT abnormalities, GI intolerance, ± cytopenia) ^(9,16)
Folinic acid	MTX overdose are acute hematological toxicity	15mg by mouth every 6h, for 2-8 doses (depending on the dose of MTX)
		Reduction of plasma homocysteine ⁽³⁰⁻³²⁾ Reversel of hematological toxicity

LFT, liver function tests.

DOES FOLATE SUPPLEMENTATION REDUCE MTX EFFICACY?

Folic acid supplementation may reduce the efficacy of MTX in the treatment of RA. Ortiz *et al.*⁹ conducted a meta-analysis and found no consistent differences in disease activity parameters when comparing placebo and folic acid; similarly, van Ede *et al.*¹⁶ found no differences in disease activity between treatment groups in a prospective study of 434 patients.

However, in the latter study, the final MTX dose was higher in folic acid patients compared to placebo patients (mean dose 18 and 14.5 mg/week, respectively), suggesting that higher doses of MTX are required to achieve the same response. Alternatively, it has been proposed that co-administration of folic acid may allow higher doses of MTX to be used before side effects occur.¹⁹ Whatever the reason, supplementing with folate allowed 83% of patients to

continue using MTX at 48 weeks, compared to only 62% of those receiving MTX alone.¹⁶

The significance of findings from large phase III trials of leflunomide in RA compared to MTX has been debated. In the American study, 52% of MTX-treated patients achieved an American College of Rheumatology 20% improvement (ACR 20), while 98% of those receiving MTX were given folic acid supplementation, compared to 65% of MTX-treated patients in the international trial, where only 11% of patients received folic acid during MTX therapy.⁽²⁰⁻²²⁾ It has been proposed that the difference in ACR 20 response can be explained by folic acid's negative effect on MTX efficacy.²¹ Post-hoc analysis of these two demographically distinct treatment groups yields no firm conclusions, not least because the American trial was placebo-controlled, whereas the international study included all patients who received an active compound. Folic acid, on the other hand, has been shown to reduce the effectiveness of MTX treatment at a dose of 15 mg per week.²³ It is likely that the timing of the folic acid in relation to the MTX, as well as the dose size, play a role in efficacy.²³ Folic acid does not have a similar effect, even at higher folate to MTX ratios.⁹ This could be explained by competition between folic acid and MTX for binding to cellular transport molecules after MTX dosing, which does not occur with folic acid.²⁴ Given the potential for disease-modifying activity improvement, the lack of benefit in preventing MTX side effects, and the significantly higher cost of folic acid, there appears to be no reason to recommend folic acid over folic acid for routine administration based on current evidence. Folic acid, on the other hand, plays an important role in the treatment of MTX overdose or acute haematological toxicity because it is a fully reduced folate that can function in biosynthetic pathways independent of dihydrofolate reductase (Table 1).

There is no agreement on folic acid dose and frequency guidelines in RA patients taking MTX. The evidence base is currently insufficient to determine the optimum dose for folic acid supplementation, and randomised controlled trials have shown that weekly folic acid doses ranging from 5 to 27.5 mg per week are effective in reducing MTX side effects.^(3,10,16) Prospective trials have not directly compared daily and once-weekly folic acid dosing schedules. A recent Scandinavian review and proposal for guidelines contends that routine supplementation is unnecessary and that the introduction of folic acid should be delayed until adverse effects or an increase in MCV occur.²⁴ This recommendation is solely based on side-

effect data and ignores the potential significant benefit in terms of cardiovascular profile.

FOLATE SUPPLEMENTATION AND CARDIOVASCULAR RISK IN RA

The importance of atherosclerotic vascular disease in RA patients is becoming better understood. RA is linked to a higher risk of death than triple-vessel coronary artery disease, and cardiovascular disease is the leading cause of death.⁽²⁵⁻²⁸⁾ Hyperhomocysteinaemia is now recognized as a distinct cardiovascular risk factor, and homocysteine levels in RA patients are frequently elevated.²⁹ As a result, MTX folate antagonism has been shown to cause an increase in plasma homocysteine levels by interfering with homocysteine demethylation to methionine via methyl tetrahydrofolate.⁽³⁰⁻³²⁾ Combination therapy with MTX and sulphasalazine, both of which may affect folate absorption or metabolism, may result in a higher increase in plasma homocysteine than MTX alone.³³

Folic acid supplementation, at doses ranging from 5 to 27.5 mg per week, has been shown to completely eliminate the MTX-induced increase in plasma homocysteine.^(30-32, 34) It has yet to be demonstrated that lowering plasma homocysteine with folic acid reduces cardiovascular risk in MTX-treated RA patients. However, folic acid and vitamin B6 supplementation has been shown to reduce the risk of developing an abnormal exercise ECG in healthy siblings of patients with premature atherosclerotic disease.³⁵

An uncontrolled retrospective study found an apparent increase in mortality in MTX-treated RA patients with documented atherosclerotic vascular disease or hypertension compared to patients with RA starting other DMARDs.³⁶ This finding contradicts findings from a recent large cohort study in Wichita.³⁷ Between 1981 and 1999, 1,240 patients with RA were followed for an average of 6 years, with 588 receiving MTX by the end of the study. After controlling for confounding factors, MTX use was linked to a 60% reduction in the risk of all-cause mortality. Other DMARDs did not show a reduction in mortality. For cardiovascular mortality, which accounted for 44% of deaths in the cohort, the mortality benefit was even greater (hazard ratio 0.3). The suppression of inflammatory mechanisms that are central to the development of atherosclerosis may explain, at least in part, a reduction in cardiovascular risk in MTX-treated patients.²⁶ Although folic acid was administered to less than 20% of the MTX-treated patients in the Wichita cohort, the combination resulted in a mortality hazard

ratio of 0.2, compared to 0.5 for MTX alone.³⁸ This adds to the evidence that folic acid supplementation may reduce cardiovascular risk in MTX-treated RA patients. There is no clear explanation for the disparities in mortality data between these two cohort studies, but both emphasise the importance of vascular morbidity in RA patients. To better understand the impact of disease-modifying drugs on mortality and cardiovascular disease, more prospective data are needed.

SUMMARY AND GUIDELINES

In conclusion, folic acid supplementation in people with RA who are taking MTX is likely to lower the incidence of liver function test abnormalities and may lower the incidence of GI intolerance and stomatitis. The incidence of significant leucopenia during MTX treatment is low, and some evidence suggests that folic acid supplementation may help. Folic acid supplementation reduces cardiovascular risk by offsetting the increase in plasma homocysteine levels associated with MTX therapy; more research is needed in this area. Folic acid supplementation has not been shown to reduce MTX efficacy in the treatment of RA, and it is likely that efficacy and common toxicity are mediated through different metabolic pathways.

Folinic acid is no more effective than folic acid in preventing MTX-related side effects, but it may reduce MTX effectiveness in some cases and is more expensive. Folinic acid, as a fully reduced folate that bypasses dihydrofolate reductase, can be used to treat acute haematological toxicity and MTX overdose. Folic acid, according to current evidence, improves MTX continuation rates without compromising efficacy. It has almost no side effects and is inexpensive (about 2 p per week in the UK).³⁹ The emerging data on cardiovascular risk in patients with inflammatory disease, as well as the potential for reducing this risk with supplemental folic acid, adds to the case for considering folic acid in MTX-treated patients.

We propose that all patients receiving MTX for the treatment of RA be given folic acid supplements on a regular basis. Although there is no data comparing the relative benefits of weekly versus daily folic acid administration, a dose of 5 mg taken orally once per week is likely to be sufficient. More research is needed to provide evidence for dose, frequency, and timing selection. The timing of folic acid administration in relation to MTX is unlikely to affect the reduction of side effects. The majority of trials have avoided administering folic acid on the same day as MTX. To reduce patient confusion and improve adherence to

treatment, we proposed a consistent and pragmatic approach to folic acid supplementation.

We recommend taking 5 mg of folic acid once a week in the morning after your MTX dose. If side effects persist, a single weekly dose of 10 mg may be considered. The results of large prospective trials examining the effect of folic acid supplementation on cardiovascular risk are awaiting publication. The increasing importance of MTX in the treatment of RA, both alone and in combination with other therapies, highlights the significance of any strategy that may improve tolerability.

REFERENCES:

1. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. *Arthritis Rheum* 1996;39:1951–60.
2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. *Am J Med Sci* 1951;221:176–82.
3. Morgan SL, Baggott JE, Vaughn WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 1990;33:9–18.
4. Hoffmeister R. Methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1972;15:114.
5. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta analysis of published clinical trials. *Arthritis Rheum* 1992;35:1117–25. [0:13 pm, 18/01/2023]
6. Ranjini TP, Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. *Immunopharmacology* 2000;47:247–57.
7. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. *Proc Natl Acad Sci USA* 1991;88:2441–5.
8. Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. *Arthritis Rheum* 1989;32:671–6.
9. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials. *J Rheumatol* 1998;25:36–43.
10. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during

- methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. *Ann Intern Med* 1994;121:833–41.
11. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. *Arthritis Rheum* 1989;32:1592–6.
 12. Griffith SM, Fisher J, Clarke S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? *Rheumatology* 2000;39:1102–9.
 13. Stewart KA, Mackenzie AH, Clough JD, Wilke WS. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. *Semin Arthritis Rheum* 1991;20:332–8.
 14. National Guidelines for the Monitoring of Second Line Drugs. London: British Society for Rheumatology, 2000.
 15. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. *Arthritis Rheum* 1996;39:723–31.
 16. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001;44:1515–24.
 17. Suzuki Y, Uehara R, Tajima C et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. *Scand J Rheumatol* 1999;28:273–81.
 18. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. *Arthritis Rheum* 2001;44:2525–30.
 19. Morgan SL, Baggott JE, Alarcon GS, Koopman WJ. Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al. *Arthritis Rheum* 2002;46:1413–4.
 20. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. *Arch Intern Med* 1999;159:2542–50.
 21. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. *Rheumatology* 2000;39:655–65.
 22. Strand V, Morgan SL, Baggott JE, Alarcon GS. Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al., and others. *Arthritis Rheum* 2000;43:2615–6.
 23. Joyce DA, Will RK, Hoffman DM, Laing B, Blackburn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. *Ann Rheum Dis* 1991;50:913–4.
 24. Endresen GK, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. *Scand J Rheumatol* 2001;30:129–34.
 25. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. *Rheumatology* 2003;42:607–13.
 26. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? *Arthritis Rheum* 2002;46:862–73.
 27. Banks M, Flint J. Rheumatoid arthritis is an independent risk factor or ischaemic heart disease. *Arthritis Rheum* 2000;43(Suppl.):S385.
 28. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. *J Rheumatol* 1998;25:1072–7.
 29. Duell PB, Malinow MR. Homocyst[e]line: an important risk factor for atherosclerotic vascular disease. *Curr Opin Lipidol* 1997;8:28–34.
 30. van Ede AE, Laan RF, Blom HJ et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. *Rheumatology* 2002;41:658–65.
 31. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. *J Rheumatol* 1998;25:441–6.
 32. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. *Scand J Rheumatol* 2001;30:305–7.
 33. Haagsma CJ, Blom HJ, van Riel PL et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. *Ann Rheum Dis* 1999;58:79–84.
 34. Jensen OK, Rasmussen C, Mollerup F et al. Hyperhomocysteinemia in rheumatoid arthritis:

- influence of methotrexate treatment and folic acid supplementation. *J Rheumatol* 2002;29:1615–8.
35. Vermeulen EG, Stehouwer CD, Twisk JW et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebocontrolled trial. *Lancet* 2000;355:517–22.
 36. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. *Lancet* 2000;355:1616–7.
 37. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002;359:1173–7.
 38. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate treatment and mortality in rheumatoid arthritis. *Lancet* 2002;360:1097–8.
 39. British National Formulary, Vol. 44. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002.